Evaluating the Efficacy of Sequential Biologic Therapies for Rheumatoid Arthritis Patients with an Inadequate Response to Tumor Necrosis Factor-Alpha Inhibitors
News Feb 17, 2011
A systematic search was undertaken to identify published peer-reviewed articles that reported clinical outcomes of biologic treatment among RA patients with an inadequate response to TNF-alpha inhibitors. Data were systematically abstracted. Efficacy rates were estimated for groups of patients who differed in the number of prior TNF-alpha inhibitors used. Endpoints included ACR- (American College of Rheumatology), EULAR- (European League Against Rheumatism) and DAS (Disease Activity Score) 28-based response criteria.
The search identified 41 publications, of which 28 reported biologic treatment outcomes for RA patients with prior exposure to TNF-alpha inhibitors. Seven publications reported outcomes obtained in randomized clinical trials, while the remaining consisted of observational studies. The likelihood of responding to a subsequent biologic treatment decreased as the number of previous treatments with TNF-alpha inhibitors increased for 6 out of the 8 response criteria examined.
For patients with prior exposure to TNF-alpha inhibitors, likelihood of response to subsequent treatment with biologic agents declines with increasing number of previous treatments with TNF-alpha inhibitors.
The full, provisional article is published online within the journal, Arthritis Research and Therapy and is free to access.
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE